Massimo Broggini

23PUBLICATIONS
64CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursChemical and thermal processes in energy and combustion
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Aug 31, 2026
Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells.

|Mar 07, 2025
The Landscape of PARP Inhibitors in Solid Cancers.

Marta Muzzana, Massimo Broggini, Giovanna Damia

|Feb 17, 2025
Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment.

Ersilia Varone, Michele Retini, Alessandro Cherubini

|Jan 02, 2024
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.

Gloriana Ndembe, Ilenia Intini, Massimo Moro

|Dec 14, 2022
Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies.

Paolo Mendogni, Roberta Affatato, Enrico Cabri

|Dec 11, 2022
NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2).

Marika Colombo, Federico Passarelli, Paola A Corsetto

Pageof 4

Frequent Collaborators

4 joint publications

Mirko Marabese

4 joint publications

Ludmila V Puchkova

2 joint publications

Marika Colombo

2 joint publications

Irina V Kiseleva